Tryp Therapeutics Inc. Stock Canadian Securities Exchange
Equities
TRYP
CA89854F1062
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 29.31M 21.42M |
---|---|---|---|---|---|
Net income 2024 * | -5M -3.65M | Net income 2025 * | -5M -3.65M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.31% |
1st Jan change | Capi. | |
---|---|---|
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |